Indivior PLC (LON: INDV)
London
· Delayed Price · Currency is GBP · Price in GBX
852.50
+15.50 (1.85%)
Nov 22, 2024, 6:33 PM BST
Indivior Revenue
Indivior had revenue of $307.00M USD in the quarter ending September 30, 2024, with 13.28% growth. This brings the company's revenue in the last twelve months to $1.18B, up 13.44% year-over-year. In the year 2023, Indivior had annual revenue of $1.09B with 21.31% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+13.44%
P/S Ratio
1.30
Revenue / Employee
$1.02M
Employees
1,164
Market Cap
1.08B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 38.20B |
GSK plc | 31.31B |
Haleon plc | 11.24B |
Smith & Nephew plc | 4.46B |
ConvaTec Group PLC | 1.74B |
Hikma Pharmaceuticals PLC | 2.39B |
Oxford Nanopore Technologies plc | 167.75M |
Animalcare Group plc | 76.10M |
Indivior News
- 3 days ago - Indivior PLC (INDV) Trading 3.1% Higher on Nov 19 - GuruFocus
- 3 days ago - Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - PRNewsWire
- 7 days ago - SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC - GuruFocus
- 15 days ago - Indivior jumps amid investor letter, takeover speculation (update) - Seeking Alpha
- 15 days ago - Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - PRNewsWire
- 23 days ago - Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - PRNewsWire
- 4 weeks ago - Indivior PLC (INDV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Indivior PLC 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha